{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:40:09Z","timestamp":1791841209990,"version":"4.3.4"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"<jats:sec id=\"ab-eoi220059-4\"><jats:title>Importance<\/jats:title><jats:p>Anti\u2013vascular endothelial growth factor (VEGF) therapy for retinopathy of prematurity (ROP) has potential ocular and systemic advantages compared with laser, but we believe the systemic risks of anti-VEGF therapy in preterm infants are poorly quantified.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220059-5\"><jats:title>Objective<\/jats:title><jats:p>To determine whether there was an association with increased risk of pulmonary hypertension (PH) in preterm infants with ROP following treatment with anti-VEGF therapy as compared with laser treatment.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220059-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This multicenter retrospective cohort study took place at neonatal intensive care units of 48 children\u2019s hospitals in the US in the Pediatric Health Information System database from 2010 to 2020. Participants included preterm infants with gestational age at birth 22 0\/7 to 31 6\/7 weeks who had ROP treated with anti-VEGF therapy or laser photocoagulation.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220059-7\"><jats:title>Exposures<\/jats:title><jats:p>Anti-VEGF therapy vs laser photocoagulation.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220059-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>New receipt of pulmonary vasodilators at least 7 days after ROP therapy was compared between exposure groups, matched using propensity scores generated from preexposure variables, and adjusted for birth year and hospital. The odds of receiving an echocardiogram after 30 days of age was also included to adjust for secular trends and interhospital variation in PH screening.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220059-9\"><jats:title>Results<\/jats:title><jats:p>Among 1577 patients (55.9% male) meeting inclusion criteria, 689 received laser photocoagulation and 888 received anti-VEGF treatment (95% bevacizumab, 5% ranibizumab). Patients were first treated for ROP at median 36.4 weeks\u2019 postmenstrual age (IQR, 34.6-38.7). A total of 982 patients (491 in each group) were propensity score matched. Good covariate balance was achieved, as indicated by a model variance ratio of 1.15. More infants who received anti-VEGF therapy were treated for PH, but when adjusted for hospital and year, this was no longer statistically significant (6.7%; 95% CI, 2.6-6.9 vs 4.3% 95% CI, 4.4-10.2; adjusted odds ratio, 1.62; 95% CI, 0.90-2.89; <jats:italic>P<\/jats:italic>\u2009=\u2009.10).<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220059-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Anti-VEGF therapy was not associated with greater use of pulmonary vasodilators after adjustment for hospital and year. Our findings suggest exposure to anti-VEGF may be associated with PH, although we cannot exclude the possibility of residual confounding based on systemic comorbidities or hospital variation in practice. Future studies investigating this possible adverse effect seem warranted.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2022.3788","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T15:40:52Z","timestamp":1665070852000},"page":"1085","source":"Crossref","is-referenced-by-count":16,"title":["Pulmonary Hypertension in Preterm Infants Treated With Laser vs Anti\u2013Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity"],"prefix":"10.1001","volume":"140","author":[{"given":"Christopher R.","family":"Nitkin","sequence":"first","affiliation":[{"name":"Children\u2019s Mercy Kansas City, Division of Neonatology, Department of Pediatrics, University of Missouri Kansas City School of Medicine, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas A.","family":"Bamat","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Philadelphia, Division of Neonatology, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Lagatta","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara B.","family":"DeMauro","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Philadelphia, Division of Neonatology, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry C.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Department of Pediatrics, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi Mangal","family":"Patel","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Children\u2019s Healthcare of Atlanta, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"King","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Department of Pediatrics, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Slaughter","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital Center for Perinatal Research and The Ohio State University, Department of Pediatrics, College of Medicine and Division of Epidemiology, College of Public Health, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Peter","family":"Campbell","sequence":"additional","affiliation":[{"name":"Casey Eye Institute, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Richardson","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Association, Lenexa, Kansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamorah","family":"Lewis","sequence":"additional","affiliation":[{"name":"Children\u2019s Mercy Kansas City, Division of Neonatology, Department of Pediatrics, University of Missouri Kansas City School of Medicine, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"eoi220059r1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.clp.2013.02.001","article-title":"Retinopathy of prematurity-incidence today.","volume":"40","author":"Zin","year":"2013","journal-title":"Clin Perinatol"},{"issue":"7","key":"eoi220059r2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"eoi220059r3","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.ophtha.2020.12.028","article-title":"Retinal detachment after treatment of retinopathy of prematurity with laser versus intravitreal anti-vascular endothelial growth factor.","volume":"128","author":"Barry","year":"2021","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi220059r4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology.","volume":"124","author":"VanderVeen","year":"2017","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi220059r5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129383","article-title":"A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity.","volume":"10","author":"Pertl","year":"2015","journal-title":"PLoS One"},{"key":"eoi220059r6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009734.pub3","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"eoi220059r7","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.3906\/sag-2101-76","article-title":"Effects of bevacizumab administration on the hypoxia-induced pulmonary hypertension rat model.","volume":"51","author":"Demir","year":"2021","journal-title":"Turk J Med Sci"},{"issue":"10","key":"eoi220059r8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"4","author":"von Elm","year":"2007","journal-title":"PLoS Med"},{"issue":"5","key":"eoi220059r9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1136\/bmjqs-2019-010730","article-title":"Variation in tonsillectomy cost and revisit rates: analysis of administrative and billing data from US children\u2019s hospitals.","volume":"30","author":"Mahant","year":"2021","journal-title":"BMJ Qual Saf"},{"issue":"12","key":"eoi220059r10","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1001\/archpediatrics.2012.1266","article-title":"Prioritization of comparative effectiveness research topics in hospital pediatrics.","volume":"166","author":"Keren","year":"2012","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"10","key":"eoi220059r13","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1377\/hlthaff.2020.00735","article-title":"Racial and ethnic inequities in children\u2019s neighborhoods: evidence from the New Child Opportunity Index 2.0.","volume":"39","author":"Acevedo-Garcia","year":"2020","journal-title":"Health Aff (Millwood)"},{"issue":"6","key":"eoi220059r14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1164\/rccm.201812-2348OC","article-title":"The diagnosis of bronchopulmonary dysplasia in very preterm infants. an evidence-based approach.","volume":"200","author":"Jensen","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"eoi220059r15","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1038\/s41372-021-01114-6","article-title":"Prioritization framework for improving the value of care for very low birth weight and very preterm infants.","volume":"41","author":"King","year":"2021","journal-title":"J Perinatol"},{"issue":"3","key":"eoi220059r16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1023\/A:1020363010465","article-title":"Using propensity scores to help design observational studies: application to the tobacco litigation.","volume":"2","author":"Rubin","year":"2001","journal-title":"Health Serv Outcomes Res Methodol"},{"issue":"1","key":"eoi220059r17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: a review and a look forward.","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci"},{"issue":"5","key":"eoi220059r18","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.survophthal.2021.02.012","article-title":"Neurodevelopmental outcomes in preterm infants with retinopathy of prematurity.","volume":"66","author":"Tan","year":"2021","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"eoi220059r19","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity.","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"issue":"2","key":"eoi220059r20","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-3537","article-title":"Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment.","volume":"144","author":"Natarajan","year":"2019","journal-title":"Pediatrics"},{"issue":"10208","key":"eoi220059r21","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"eoi220059r22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/bjophthalmol-2017-310408","article-title":"Ultra-low-dose intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case series.","volume":"102","author":"Hillier","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"eoi220059r23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jaapos.2017.10.006","article-title":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity.","volume":"22","author":"Kennedy","year":"2018","journal-title":"J AAPOS"},{"key":"eoi220059r24","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1740347","article-title":"Respiratory complications in infants with retinopathy of prematurity (ROP) requiring laser photocoagulation.","author":"Arthur","year":"2021","journal-title":"Am J Perinatol"},{"issue":"2","key":"eoi220059r25","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity.","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"eoi220059r26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"eoi220059r27","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity.","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"issue":"6","key":"eoi220059r28","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jamaophthalmol.2020.0334","article-title":"Short-term outcomes after very low-dose intravitreous bevacizumab for retinopathy of prematurity.","volume":"138","author":"Wallace","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"eoi220059r29","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity.","volume":"256","author":"Huang","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"eoi220059r30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10384-021-00895-9","article-title":"Serum vascular endothelial growth factor, insulin-like growth factor-1 and aflibercept levels in retinopathy of prematurity.","volume":"66","author":"Furuncuoglu","year":"2022","journal-title":"Jpn J Ophthalmol"},{"issue":"12","key":"eoi220059r31","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis).","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi220059r32","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1177\/019262339902700507","article-title":"Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration.","volume":"27","author":"Mordenti","year":"1999","journal-title":"Toxicol Pathol"},{"issue":"8","key":"eoi220059r33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1167\/tvst.9.8.43","article-title":"Ranibizumab population pharmacokinetics and free VEGF pharmacodynamics in preterm infants with retinopathy of prematurity in the RAINBOW trial.","volume":"9","author":"Fidler","year":"2020","journal-title":"Transl Vis Sci Technol"},{"issue":"21","key":"eoi220059r34","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1161\/CIR.0000000000000329","article-title":"Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society.","volume":"132","author":"Abman","year":"2015","journal-title":"Circulation"},{"issue":"4","key":"eoi220059r35","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41372-021-00965-3","article-title":"Specificity of International Classification of Diseases codes for bronchopulmonary dysplasia: an investigation using electronic health record data and a large insurance database.","volume":"41","author":"Beam","year":"2021","journal-title":"J Perinatol"},{"issue":"1","key":"eoi220059r36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1001\/jamaophthalmol.2013.577","article-title":"Accuracy of international classification of diseases, ninth revision, clinical modification billing codes for common ophthalmic conditions.","volume":"131","author":"Muir","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"eoi220059r37","doi-asserted-by":"publisher","DOI":"10.1080\/09286586.2022.2036766","article-title":"Association of cardiovascular disease with retinopathy of prematurity.","author":"Bhatti","journal-title":"Ophthalmic Epidemiol"},{"key":"eoi220059r38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jpeds.2017.05.029","article-title":"Evaluation and management of pulmonary hypertension in children with bronchopulmonary dysplasia.","volume":"188","author":"Krishnan","year":"2017","journal-title":"J Pediatr"},{"key":"eoi220059r11","unstructured":"Brandeis University, The Heller School for Social Policy and Management. Child Opportunity Index 2.0 ZIP code estimates. Accessed September 2, 2022. https:\/\/www.diversitydatakids.org\/"},{"key":"eoi220059r12","unstructured":"Noelke? C, McArdle? N, Baek? M, ; Diversity Data Kids. How we built it. Accessed September 2, 2022. http:\/\/new.diversitydatakids.org\/research-library\/research-brief\/how-we-built-it"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2797005\/jamaophthalmology_nitkin_2022_oi_220059_1668089436.82782.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T16:02:49Z","timestamp":1668700969000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2797005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.3788","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}